Linking cognitive variability and Alzheimer's disease biomarkers by neurocognitive status

Editorial: Advances in Memory and Cognitive Decline Associated with Aging and Alzheimer’s Disease

Alzheimer's disease is a progressive neurodegenerative disease in the elderly population [...].

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate.

Complement system and glial activation biomarkers in cerebrospinal fluid: correlation with Alzheimer’s pathology

Mapping sex‐specific associations of adiposity with age‐related cognitive decline and multimodal Alzheimer's pathology

The adiposity–cognition relationship in aging is controversial. This study aimed to assess its sex‐ and age‐specific associations with Alzheimer’s disease (AD) pathology using multimodal biomarkers.